These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 25382609)

  • 21. Efficacy and safety profile of long-term exposure to lenalidomide in patients with recurrent multiple myeloma.
    Fouquet G; Tardy S; Demarquette H; Bonnet S; Gay J; Debarri H; Herbaux C; Guidez S; Michel J; Perrot A; Serrier C; Miljkovic D; Avet Loiseau H; Facon T; Hulin C; Leleu X
    Cancer; 2013 Oct; 119(20):3680-6. PubMed ID: 23921945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study.
    Jakubowiak AJ; Richardson PG; Zimmerman T; Alsina M; Kaufman JL; Kandarpa M; Kraftson S; Ross CW; Harvey C; Hideshima T; Sportelli P; Poradosu E; Gardner L; Giusti K; Anderson KC
    Br J Haematol; 2012 Aug; 158(4):472-80. PubMed ID: 22640031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.
    Dimopoulos MA; Palumbo A; Corradini P; Cavo M; Delforge M; Di Raimondo F; Weisel KC; Oriol A; Hansson M; Vacca A; Blanchard MJ; Goldschmidt H; Doyen C; Kaiser M; Petrini M; Anttila P; Cafro AM; Raymakers R; San-Miguel J; de Arriba F; Knop S; Röllig C; Ocio EM; Morgan G; Miller N; Simcock M; Peluso T; Herring J; Sternas L; Zaki MH; Moreau P
    Blood; 2016 Jul; 128(4):497-503. PubMed ID: 27226434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Vesole DH; Bilotti E; Richter JR; McNeill A; McBride L; Raucci L; Anand P; Bednarz U; Ivanovski K; Smith J; Batra V; Aleman A; Sims T; Guerrero L; Mato A; Siegel DS
    Br J Haematol; 2015 Oct; 171(1):52-9. PubMed ID: 26018491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. "Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.
    Katodritou E; Vadikolia C; Lalagianni C; Kotsopoulou M; Papageorgiou G; Kyrtsonis MC; Matsouka P; Giannakoulas N; Kyriakou D; Karras G; Anagnostopoulos N; Michali E; Briasoulis E; Hatzimichael E; Spanoudakis E; Zikos P; Tsakiridou A; Tsionos K; Anargyrou K; Symeonidis A; Maniatis A; Terpos E
    Ann Hematol; 2014 Jan; 93(1):129-39. PubMed ID: 23892921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
    Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
    Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
    Sun HL; Atenafu EG; Yeboah E; Reece DE; Trudel S; Kukreti V; Masih-Khan E; Winter A; Chen C
    Leuk Lymphoma; 2015 Feb; 56(2):407-14. PubMed ID: 24738975
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Upfront lower dose lenalidomide is less toxic and does not compromise efficacy for vulnerable patients with relapsed refractory multiple myeloma: final analysis of the phase II RevLite study.
    Quach H; Fernyhough L; Henderson R; Corbett G; Baker B; Browett P; Blacklock H; Forsyth C; Underhill C; Cannell P; Trotman J; Neylon A; Harrison S; Link E; Swern A; Cowan L; Dimopoulos MA; Miles Prince H
    Br J Haematol; 2017 May; 177(3):441-448. PubMed ID: 28197996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lenalidomide: a review of its use in the treatment of relapsed or refractory multiple myeloma.
    Scott LJ; Lyseng-Williamson KA
    Drugs; 2011 Mar; 71(5):625-49. PubMed ID: 21443285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
    Schjesvold FH; Dimopoulos MA; Delimpasi S; Robak P; Coriu D; Legiec W; Pour L; Špička I; Masszi T; Doronin V; Minarik J; Salogub G; Alekseeva Y; Lazzaro A; Maisnar V; Mikala G; Rosiñol L; Liberati AM; Symeonidis A; Moody V; Thuresson M; Byrne C; Harmenberg J; Bakker NA; Hájek R; Mateos MV; Richardson PG; Sonneveld P;
    Lancet Haematol; 2022 Feb; 9(2):e98-e110. PubMed ID: 35032434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone
    Mateos MV; Masszi T; Grzasko N; Hansson M; Sandhu I; Pour L; Viterbo L; Jackson SR; Stoppa AM; Gimsing P; Hamadani M; Borsaru G; Berg D; Lin J; Di Bacco A; van de Velde H; Richardson PG; Moreau P
    Haematologica; 2017 Oct; 102(10):1767-1775. PubMed ID: 28751562
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
    Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
    Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
    [TBL] [Abstract][Full Text] [Related]  

  • 33. United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma.
    Davies F; Morris C; Bird J; Cook G; Williams C; Tighe J; Cavenagh J; Behrens J; Schey S; Morgan G;
    Int J Lab Hematol; 2009 Apr; 31(2):119-31. PubMed ID: 19016917
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
    Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
    N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.
    Richardson PG; Xie W; Jagannath S; Jakubowiak A; Lonial S; Raje NS; Alsina M; Ghobrial IM; Schlossman RL; Munshi NC; Mazumder A; Vesole DH; Kaufman JL; Colson K; McKenney M; Lunde LE; Feather J; Maglio ME; Warren D; Francis D; Hideshima T; Knight R; Esseltine DL; Mitsiades CS; Weller E; Anderson KC
    Blood; 2014 Mar; 123(10):1461-9. PubMed ID: 24429336
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
    Zago M; Oehrlein K; Rendl C; Hahn-Ast C; Kanz L; Weisel K
    Ann Hematol; 2014 Dec; 93(12):1993-9. PubMed ID: 24974802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
    Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
    Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib.
    Richardson PG; Siegel D; Baz R; Kelley SL; Munshi NC; Laubach J; Sullivan D; Alsina M; Schlossman R; Ghobrial IM; Doss D; Loughney N; McBride L; Bilotti E; Anand P; Nardelli L; Wear S; Larkins G; Chen M; Zaki MH; Jacques C; Anderson KC
    Blood; 2013 Mar; 121(11):1961-7. PubMed ID: 23243282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.
    Dimopoulos MA; Stewart AK; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel D; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak A; San-Miguel J; Ludwig H; Ro S; Aggarwal S; Moreau P; Palumbo A
    Blood Cancer J; 2017 Apr; 7(4):e554. PubMed ID: 28430175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma--real life experience of a tertiary cancer center.
    João C; Coelho I; Costa C; Esteves S; Lucio P
    Ann Hematol; 2015 Jan; 94(1):97-105. PubMed ID: 25038919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.